UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 13,
2011
CLEVELAND
BIOLABS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-32954
|
20-0077155
|
||
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
73
High Street
Buffalo, New York
14203
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (716) 849-6810
_____________________________________________________________________________________
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On January 13, 2011, the Compensation
Committee of the Board of Directors of Cleveland BioLabs, Inc. (the “Company”)
approved the increase in base salary, the payment of cash bonuses and the
issuance of stock options to its executive officers: Michael Fonstein, Yakov
Kogan, John A. Marhofer, Jr., and Andrei Gudkov. The base salary increases,
which will go into effect on January 1, 2011, cash bonuses and award of stock
options are in recognition of Company performance in 2010. The cash bonuses are
payable in January 2011 and the stock options will be awarded in compliance with
the Company’s Equity Award Guidelines and Insider Trading Policy and will vest
immediately when granted.
The following table sets forth the new
base salaries, cash bonuses and stock options of these executive officers, as
approved:
Name
|
Base Salary | Cash Bonus |
Stock Options
|
||
Michael
Fonstein
|
$ |
335,320
|
$ |
76,600
|
149,609
|
Yakov
Kogan
|
261,969
|
59,844
|
149,609
|
||
John
A. Marhofer, Jr.
|
220,054
|
50,269
|
149,609
|
||
Andrei
Gudkov
|
136,224
|
62,238
|
149,609
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly
authorized.
CLEVELAND BIOLABS, INC. | |||
|
By:
|
/s/ John A. Marhofer, Jr. | |
Name: John A. Marhofer, Jr. | |||
Title: Chief Financial Officer | |||
Date:
January 14, 2011